<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5272">
  <stage>Registered</stage>
  <submitdate>22/06/2015</submitdate>
  <approvaldate>22/06/2015</approvaldate>
  <nctid>NCT02485652</nctid>
  <trial_identification>
    <studytitle>Phase II Trial of HM61713 for the Treatment of =2nd Line T790M Mutation Positive Adenocarcinoma of the Lung</studytitle>
    <scientifictitle>A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-001435-21</secondaryid>
    <secondaryid>HM-EMSI-202</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non Small Cell Lung Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - HM61713

Experimental: HM61713 - HM61713 800 mg (2 x 400 mg tablets) once daily (QD)


Treatment: drugs: HM61713
800 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigator?s opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Objective response rate (ORR) - To assess the anti-tumor efficacy of HM61713 as measured by objective response rate (ORR).</outcome>
      <timepoint>At baseline and every 6 weeks from time of first dose until date of progression, assessed up to 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Disease control rate (DCR), defined as the proportion of patients with a documented CR, PR, and SD during the treatment cycles according to the RECIST version 1.1 - To assess clinical efficacy of HM61713 regarding disease control rate (DCR).</outcome>
      <timepoint>At baseline and every 6 weeks from time of first dose until date of progression, assessed up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of overall tumor response (DR), defined as the interval between the date of the first observation of tumor response (CR or PR) and the date of disease progression or death - To assess clinical efficacy of HM61713 regarding Duration of overall tumor response (DR).</outcome>
      <timepoint>At baseline and every 6 weeks from time of first dose until date of progression, assessed up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival (PFS), defined as the time from first administration of study drug to determination of tumor progression by RECIST version 1.1 or death due to any cause, whichever occurs first - To assess clinical efficacy of HM61713 regarding Progression-free survival (PFS).</outcome>
      <timepoint>At baseline and every 6 weeks from time of first dose until date of progression, assessed up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival (OS), defined as the time from first administration of study drug until death from any cause - To assess clinical efficacy of HM61713 regarding Overall survival (OS).</outcome>
      <timepoint>From first dose to end of study or date of death from any cause whichever came first, assessed up to 48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to progression (TTP), defined as the time from first administration of study drug to determination of tumor progression by RECIST version 1.1 - To assess clinical efficacy of HM61713 regarding Time to progression (TTP).</outcome>
      <timepoint>At baseline and every 6 weeks from time of first dose until date of progression, assessed up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tumor shrinkage calculated as absolute change and percentage change from baseline in sum of tumor size at each assessment using RECIST tumor response - To assess clinical efficacy of HM61713 regarding tumor shrinkage.</outcome>
      <timepoint>At baseline and every 6 weeks from time of first dose until date of progression, assessed up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Peak concentration (Cmax) of HM61713 - To determine the pharmacokinetic (PK) profile of HM61713.</outcome>
      <timepoint>Pre-dose (-30 to 0 mins) and 1 hour (± 5 mins), 3, 4, 6 hours (± 10 mins) on Day 1 and Day 15 of Cycle 1 and pre-dose (-30 to 0 mins) only on Day 8 of Cycle 1 and Day 1 of Cycle 2 (Day 22)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough plasma concentration (Ctrough) of HM61713 - To determine the pharmacokinetic (PK) profile of HM61713.</outcome>
      <timepoint>Pre-dose (-30 to 0 mins) and 1 hour (± 5 mins), 3, 4, 6 hours (± 10 mins) on Day 1 and Day 15 of Cycle 1 and pre-dose (-30 to 0 mins) only on Day 8 of Cycle 1 and Day 1 of Cycle 2 (Day 22)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration time curve over the 24-hour dosing interval (AUC) of HM61713 - To determine the pharmacokinetic (PK) profile of HM61713.</outcome>
      <timepoint>Pre-dose (-30 to 0 mins) and 1 hour (± 5 mins), 3, 4, 6 hours (± 10 mins) on Day 1 and Day 15 of Cycle 1 and pre-dose (-30 to 0 mins) only on Day 8 of Cycle 1 and Day 1 of Cycle 2 (Day 22)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient reported outcomes (PROs) - To assess patient reported outcomes (PROs) of health-related quality of life (HRQoL), disease/treatment-related symptoms of lung cancer, and general health status.</outcome>
      <timepoint>At baseline and every 6 weeks from time of discontinuation, assessed up to 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>ECG/QTc (absolute values and change from baseline) - To evaluate the effect of HM61713 on the QT interval.</outcome>
      <timepoint>Adverse events will be collected from baseline until 28 days after the last dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of reported AEs and abnormal laboratory tests (AEs will be assessed using the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 4). - To assess the safety and tolerability of HM61713.</outcome>
      <timepoint>Adverse events will be collected from baseline until 28 days after the last dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>QTc interval as assessed by digital ECG with central reading. The QT interval will be rate-corrected using 3 methods: QTcF, QTcB and QTcS. - To assess the safety and tolerability of HM61713.</outcome>
      <timepoint>Adverse events will be collected from baseline until 28 days after the last dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age: at least 20 years of age

          -  Cytologically or histologically confirmed adenocarcinoma of locally advanced or
             metastatic NSCLC which is not amenable to curative surgery or radiotherapy

          -  Radiologically confirmed disease progression after at least one line of treatment with
             an EGFR-TKI

          -  At least one documented EGFR mutation which is known to be related with susceptibility
             to EGFR-TKIs (including G719X, exon 19 deletion, L858R, and L861Q)

          -  World Health Organization (WHO) performance score of 0 to 1 with life expectancy of at
             least 3 months

          -  Centrally confirmed T790M mutation positive tumor status from a tumor sample taken
             after confirmation of disease progression on the most recent anticancer treatment
             regimen

          -  At least one lesion (excluding the brain), not previously irradiated that can be
             accurately measured per RECIST version 1.1

          -  Adequate hematological and biological function

          -  Females of child-bearing potential must agree to use adequate contraception and for 3
             months after the last dose of study drug

          -  Male patients should be documented to be sterile or agree to use barrier contraception

          -  Recovery to = Grade 1 or baseline of any toxicities, except for stable sensory
             neuropathy = Grade 2 and alopecia</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known history of hypersensitivity to active or inactive excipients of HM61713 or drugs
             with a similar chemical structure of HM61713

          -  Previous treatment with anticancer therapies, EGFR-TKI, HM61713, or other drugs that
             target T790M-positive mutant EGFR with sparing of wild-type, investigational agent(s)
             within 28 days prior to the first administration of study drug, radiotherapy

          -  Any non-study related significant surgical procedures within the past 28 days prior to
             the first administration of study drug

          -  Spinal cord compression, leptomeningeal carcinomatosis or active symptomatic brain
             metastases

          -  History of any other malignancy

          -  Clinically significant uncontrolled condition(s)

          -  Active or chronic pancreatitis

          -  Anyone with cardiac abnormalities or history

          -  Presence or history of ILD, drug-induced ILD, or presence of radiation pneumonitis

          -  Pregnant or breast feeding

          -  In the opinion of the investigator, the patient is an unsuitable candidate to receive
             HM61713</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>162</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Research Site - Darlinghurst</hospital>
    <hospital>Research site - Fitzroy</hospital>
    <hospital>Research Site - Frankston</hospital>
    <hospital>Research Site - Kogarah</hospital>
    <hospital>Research Site - St Albans</hospital>
    <hospital>Research Site - Woolloongabba</hospital>
    <postcode> - Darlinghurst</postcode>
    <postcode> - Fitzroy</postcode>
    <postcode> - Frankston</postcode>
    <postcode> - Kogarah</postcode>
    <postcode> - St Albans</postcode>
    <postcode> - Woolloongabba</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Homburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bergamo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Catania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Cheongju-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Goyang-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Hwasun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Incheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seongnam-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Penang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuantan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuching</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Kalakhang Maynila</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Manila</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Metro Manila</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Cebu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>La Coruna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Navarra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>San Sebastian</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Tainan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hanmi Pharmaceutical Company Limited</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of HM61713
      in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an
      epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02485652</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Keunchil Park, M.D., Ph.D</name>
      <address>Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>